Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Kabi AG

Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com

Latest From Fresenius Kabi AG

BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact

Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.

Biosimilars Legal Issues

Boehringer Settlement Jumps The Queue For Biosimilar Adalimumab

Boehringer Ingelheim has settled litigation with AbbVie over Humira by striking a deal that allows it to launch its biosimilar adalimumab in the US from the start of July 2023.

Biosimilars Deals

EU Biosimilar Filings, Opinions And Approvals

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
European Performance Tracker Approvals

Kabi Holds To US Prices Even As Injectables Volumes Slip

Fresenius Kabi is comfortable with foregoing some volumes in the US generic injectables arena to protect prices and margins. But it is ready to cut prices if the competitive supply situation shifts.

Business Strategies North America
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register